Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 clinical trial for its lead drug candidate, Lucid-MS, according to a press release. The announcement was featured in a BioMedWire editorial titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” which highlights the drug’s potential to protect and repair myelin sheath, the protective covering of nerve fibers that is damaged in multiple sclerosis (MS).
Unlike existing MS treatments that target the immune system to reduce inflammation, Lucid-MS is a patented, first-in-class small molecule designed to directly address the underlying cause of MS by preventing and reversing myelin degradation. In preclinical models, the drug has shown the ability to restore myelin, offering hope for a disease-modifying therapy that could potentially halt or even reverse disability progression in MS patients.
The FDA’s clearance for a Phase 2 trial is a significant milestone for the micro-cap biotech, as few drug candidates advance to this stage. This progress has already caught the attention of Wall Street analysts, who have issued a new buy rating on the stock, according to the editorial.
“This is a critical step forward for our company and for patients living with MS,” said a spokesperson for Quantum BioPharma. “We believe Lucid-MS has the potential to change the treatment paradigm for this debilitating disease.”
Multiple sclerosis affects approximately 2.8 million people worldwide, according to the National Multiple Sclerosis Society. Current therapies can reduce relapse rates and slow progression, but they do not repair the myelin damage that leads to accumulating neurological disability. Lucid-MS aims to fill that gap.
The Phase 2 trial will evaluate the safety and efficacy of Lucid-MS in patients with relapsing forms of MS. The study is expected to enroll a significant number of participants and will measure outcomes such as reduction in new brain lesions and improvements in disability scales.
Quantum BioPharma, a biopharmaceutical company focused on neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, is developing Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc. The company also holds a 19.84% stake in Unbuzzd Wellness Inc., which markets an OTC version of its alcohol misuse product, unbuzzd(TM), and is entitled to royalty payments from its sales.
The editorial noted that the FDA clearance is a rare achievement for a micro-cap biotech, and the company’s progress could attract further investor interest. “Lucid-MS represents a novel approach to MS treatment, and the successful completion of Phase 2 trials could position Quantum BioPharma as a leader in neurorepair,” the editorial stated.
For more information on the full press release, visit https://ibn.fm/dwwiP.
